American Association for Cancer Research
15357163mct191069-sup-232418_3_supp_6203552_q85qxv.pdf (262.09 kB)

Supplementary Figure S1 from Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor

Download (262.09 kB)
journal contribution
posted on 2023-04-03, 18:22 authored by Alfonso García-Valverde, Jordi Rosell, Garazi Serna, Claudia Valverde, Joan Carles, Paolo Nuciforo, Jonathan A. Fletcher, Joaquín Arribas, Oliver Politz, César Serrano

Tumor volume (mm3) in four treatment arms at different time points in GIST-T1 (A) and GIST-T1/670 (B) in vivo models. Mean {plus minus} SEM.



KIT or PDGFRA gain-of-function mutations are the primary drivers of gastrointestinal stromal tumor (GIST) growth and progression throughout the disease course. The PI3K/mTOR pathway is critically involved in the transduction of KIT/PDGFRA oncogenic signaling regardless of the type of primary and secondary mutations, and therefore emerges as a relevant targetable node in GIST biology. We evaluated in GIST preclinical models the antitumor activity of copanlisib, a novel pan-class-I PI3K inhibitor with predominant activity against p110α and p110δ isoforms, as single-agent and in combination with first-line KIT inhibitor imatinib. In vitro studies undertaken in one imatinib-sensitive (GIST-T1) and two imatinib-resistant (GIST-T1/670 and GIST430/654) GIST cell models showed that single-agent copanlisib effectively suppressed PI3K pathway activation leading to decreased cell viability and proliferation in both imatinib-sensitive and -resistant cells irrespective of the type of primary or secondary KIT mutations. Simultaneous PI3K and KIT inhibition with copanlisib and imatinib resulted in enhanced impairment of cell viability in both imatinib-sensitive and -resistant GIST cell models, although apoptosis was mostly triggered in GIST-T1. Single-agent copanlisib inhibited GIST growth in vivo, and conjoined inhibition of PI3K and KIT was the most active therapeutic intervention in imatinib-sensitive GIST-T1 xenografts. IHC stain for cleaved-caspase 3 and phospho-S6 support a predominant antiproliferative effect of copanlisib in GIST. In conclusion, copanlisib has single-agent antitumor activity in GIST regardless KIT mutational status or sensitivity to imatinib. Effective KIT inhibition is necessary to achieve synergistic or additive effects with the combination of imatinib and any given PI3K/mTOR pathway inhibition.